Diabetic Macular Edema (DME) Global Market Report 2025

The diabetic macular edema (DME) market size has grown steadily in recent years. It will grow from $4.67 billion in 2024 to $4.89 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to the rise in the prevalence of diabetes, an increase in edema-related disorders, the growing prevalence of diabetic eye diseases, a surge in the geriatric population, and an increase in cases of blindness.

The diabetic macular edema (DME) market size is expected to see steady growth in the next few years. It will grow to $5.82 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The anticipated growth during the forecast period is driven by improved healthcare access, increased government healthcare funding, greater awareness of diabetic complications, the growing adoption of telemedicine for eye care, and the expansion of specialized diabetic eye care centers. Key trends include the development of anti-VEGF therapies, the adoption of corticosteroid implants, advancements in drug delivery systems, innovations in retinal laser treatments, AI-powered diagnostic tools, and the increasing use of minimally invasive surgical techniques.

The rising prevalence of diabetes is anticipated to propel the growth of the diabetic macular edema (DME) market. Factors such as sedentary lifestyles, unhealthy dietary habits, increasing obesity rates, aging populations, and genetic predisposition contribute to the growing incidence of diabetes. This condition leads to diabetic macular edema by damaging retinal blood vessels, causing fluid leakage into the macula and resulting in swelling. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people worldwide were living with diabetes. This number is projected to more than double, reaching 1.3 billion by 2050. Consequently, the increasing prevalence of diabetes is driving the expansion of the diabetic macular edema (DME) market.

Leading companies in the diabetic macular edema (DME) treatment sector are emphasizing technological advancements, particularly in drug therapies, to enhance patient management and treatment outcomes. These advanced drug therapies incorporate innovative technologies and research to improve treatment efficacy, minimize side effects, and provide better results for patients. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced the European Commission's approval of Beovu for treating visual impairment caused by diabetic macular edema (DME). This approval was based on Phase III KESTREL and KITE study findings, which demonstrated Beovu's comparable effectiveness to aflibercept in improving vision over a one-year period. Additionally, more than half of the patients treated with Beovu maintained a 12-week treatment schedule, experiencing fewer instances of retinal fluid compared to those treated with aflibercept.

In July 2024, Merck & Co Inc, a US-based pharmaceutical company, acquired Eyebiotech Limited for $1.3 billion. This acquisition strengthens Merck & Co.’s portfolio, enhances research capabilities, and provides access to Restoret (EYE-103), a promising treatment for diabetic macular edema (DME) and treatment-naive neovascular age-related macular degeneration (AMD). Through this acquisition, the company aims to address significant unmet needs in ophthalmology. Eyebiotech Limited (EyeBio) is a UK-based biotechnology company specializing in ophthalmology.

Major players in the diabetic macular edema (dme) market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Carl Zeiss AG, Topcon Corporation, Ypsomed AG, ARKRAY Inc, Hugel Inc., Optos plc, Noven Pharmaceuticals Inc., Alimera Sciences Inc., and Allergan plc.

North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic macular edema (DME) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic macular edema (DME) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diabetic macular edema (DME) is a diabetes-related complication characterized by fluid accumulation in the macula, the central part of the retina responsible for sharp vision. This swelling occurs due to damaged blood vessels leaking fluid and proteins into the retinal tissue, leading to vision impairment or potential blindness if left untreated. DME is a leading cause of vision loss among diabetic patients and is closely linked to diabetic retinopathy.

The primary treatments for diabetic macular edema (DME) include anti-VEGF therapy, corticosteroids, laser therapy, and surgical intervention. Anti-VEGF therapy works by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel growth and retinal leakage, contributing to DME. The disease progresses through different stages, including early, moderate, and advanced stages. Patient demographics are categorized by age groups, including adults, the elderly, and children. Routes of administration include intravitreal injection, topical application, and systemic methods, with distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The diabetic macular edema (DME) market research report is one of a series of new reports that provides diabetic macular edema (DME) market statistics, including the diabetic macular edema (DME) industry's global market size, regional shares, competitors with a diabetic macular edema (DME) market share, detailed diabetic macular edema (DME) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic macular edema (DME) industry. This diabetic macular edema (DME) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diabetic macular edema (DME) market consists of revenues earned by entities by providing services such as retinal imaging, fluorescein angiography, visual acuity testing, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic macular edema market includes sales of ranibizumab, aflibercep, fluocinolone acetonide intravitreal implant, and dexamethasone intravitreal implant. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.